What Cortexyme Inc.’s chief operating officer Christopher Lowe called “a giant step forward” in Alzheimer’s disease (AD) research with atuzaginstat (COR-388) was viewed...

Diacarta Inc.’s diagnostic assay, Coloscape, could be the first to meet the Centers for Medicare and Medicaid Service (CMS)’s strict standards for Medicare coverage of a...

The Cancer Grand Challenges Mutographs study, a combined genetic and epidemiological analysis of data from eight countries with widely different incidences of esophageal squamous cell carcinomas (ESCC), has unexpectedly failed to identify mutational signatures indicating DNA damage that could account for global ESCC incidence variations.

Innovent Biologics Co. Ltd.’s phase III Orient-31 trial for sintilimab in EGFR-mutated nonsquamous non-small-cell lung cancer (nsqNSCLC) met its primary endpoint. In...